Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTK2 | Q05397 | 1/20 | 0.48 |
| ▸ | ABL1 | P00519 | 7/20 | 0.47 |
| ▸ | DEGS1 | O15121 | 1/20 | 0.44 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.43 |
| ▸ | GAA | P10253 | 1/20 | 0.43 |
| ▸ | SYK | P43405 | 1/20 | 0.43 |
| ▸ | MET | P08581 | 1/20 | 0.43 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.41 |
| ▸ | GLS | O94925 | 1/20 | 0.41 |
| ▸ | ACACB | O00763 | 3/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.41 |
| ▸ | LMNA | P02545 | 1/20 | 0.41 |
| ▸ | ACACA | Q13085 | 1/20 | 0.41 |
| ▸ | MEN1 | O00255 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12935883 | 0.87 | PTK2 (0.54) | PTK2ABL1CYP1A2GAAMET | |
| SCHEMBL27211106 | 0.85 | ABL1 (0.44) | ABL1DEGS1KMT2AALDH1A1LMNA | |
| SCHEMBL32666977 | 0.78 | PTK2 (0.51) | PTK2ABL1DEGS1CYP1A2GAA | |
| SCHEMBL32667084 | 0.78 | ABL1 (0.56) | PTK2ABL1 | |
| SCHEMBL26802297 | 0.76 | PTK2 (0.56) | PTK2DEGS1CYP1A2GAAMET | |
| SCHEMBL32667187 | 0.76 | ABL1 (0.53) | PTK2ABL1CYP1A2GAAGLS | |
| SCHEMBL13090478 | 0.76 | ABL1 (0.64) | ABL1DEGS1KMT2AALDH1A1MEN1 | |
| SCHEMBL8794754 | 0.76 | PTK2 (0.59) | PTK2DEGS1CYP1A2GAAMET | |
| SCHEMBL2852311 | 0.75 | GCK (0.49) | ABL1KMT2AACACBALDH1A1LMNA | |
| SCHEMBL31492989 | 0.75 | MAPK8 (0.44) | ABL1SYK |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260028365-A1 | TYROSINE KINASE 2 INHIBITORS AND USES THEREOF | BIOGEN MA INC (US) | 2026-01-29 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20260028365-A1 | TYROSINE KINASE 2 INHIBITORS AND USES THEREOF | TYK2, ERBB2, ROS1 | PTK2 38/4885ABL1 5/4885DEGS1 2869/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.